** Shares in Genmab GMAB.CO fall 5.4% after Johnson & Johnson JNJ.N opted out of further clinical development of the Hexabody-CD38 cancer drug on Monday
** Van Lanschot Kempen says that Hexabody did not differentiate enough from Darzalex, the company's flagship drug, and neither Genmab nor J&J will take the project forward
** While Kempen says "the shares are now free to perform" without this overhang, Jyske Bank does not expect a quick rebound but rather a slow regain of market confidence
** Kempen expects continued earnings momentum and growing appreciation for another cancer drug Epkinly as a major growth driver
** Genmab says J&J opt-out does not impact its 2025 guidance
(Reporting by Vera Dvorakova and Jesus Calero)
((vera.dvorakova@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。